{"id":"quetiapine-fumarate-sustained-release","safety":{"commonSideEffects":[{"rate":"15-25%","effect":"Somnolence/sedation"},{"rate":"10-15%","effect":"Dry mouth"},{"rate":"10-15%","effect":"Dizziness"},{"rate":"5-10%","effect":"Weight gain"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Constipation"},{"rate":"5%","effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Quetiapine blocks dopamine and serotonin receptors, which reduces psychotic symptoms and stabilizes mood. The sustained-release formulation provides extended drug delivery over 24 hours, allowing once-daily dosing while maintaining therapeutic levels. This mechanism is thought to normalize neurotransmitter activity in brain regions associated with psychosis, mania, and depression.","oneSentence":"Quetiapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:37.130Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute mania and maintenance)"},{"name":"Major depressive disorder (adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT00206115","phase":"PHASE3","title":"SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-11","conditions":"Schizophrenic Disorder","enrollment":535},{"nctId":"NCT00234377","phase":"PHASE3","title":"Seroquel Switching Study: Feasibility of Switching Any Antipsychotic Treatment to Seroquel in Patients With Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-11","conditions":"Schizophrenia","enrollment":550},{"nctId":"NCT00206128","phase":"PHASE3","title":"Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-11","conditions":"Schizophrenia","enrollment":454},{"nctId":"NCT00228462","phase":"PHASE3","title":"Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-03","conditions":"Schizophrenia","enrollment":197},{"nctId":"NCT00389064","phase":"PHASE3","title":"Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Anxiety Disorders","enrollment":450},{"nctId":"NCT00675896","phase":"PHASE4","title":"A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome","status":"COMPLETED","sponsor":"Dr Alexander McIntyre Inc.","startDate":"2007-04","conditions":"Major Depression","enrollment":120},{"nctId":"NCT00351910","phase":"PHASE3","title":"Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Major Depressive Disorder","enrollment":494},{"nctId":"NCT00388973","phase":"PHASE3","title":"Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Major Depressive Disorder","enrollment":338},{"nctId":"NCT00329446","phase":"PHASE3","title":"Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Generalized Anxiety Disorder","enrollment":800},{"nctId":"NCT00085891","phase":"PHASE3","title":"Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-06","conditions":"Schizophrenia","enrollment":535},{"nctId":"NCT00320268","phase":"PHASE3","title":"Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Major Depressive Disorder","enrollment":600},{"nctId":"NCT00329264","phase":"PHASE3","title":"Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Generalized Anxiety Disorder","enrollment":876},{"nctId":"NCT00278941","phase":"PHASE3","title":"Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-12","conditions":"Major Depressive Disorder","enrollment":3000},{"nctId":"NCT00321490","phase":"PHASE3","title":"Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Major Depressive Disorder","enrollment":600},{"nctId":"NCT00422214","phase":"PHASE3","title":"Phase III/Seroquel SR Bipolar Depression Monotherapy - US","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-12","conditions":"Affective Psychosis, Bipolar, Depression, Bipolar, Manic-Depressive Psychosis","enrollment":400},{"nctId":"NCT00326144","phase":"PHASE3","title":"Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Major Depressive Disorder","enrollment":310},{"nctId":"NCT00326105","phase":"PHASE3","title":"Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Major Depressive Disorder","enrollment":450},{"nctId":"NCT00422123","phase":"PHASE3","title":"Phase 3 /Seroquel SR Acute Mania Monotherapy - US","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Affective Psychosis, Bipolar, Manic Disorder, Manic-Depressive Psychosis","enrollment":447},{"nctId":"NCT00351169","phase":"PHASE3","title":"Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Major Depressive Disorder","enrollment":450},{"nctId":"NCT00322595","phase":"PHASE3","title":"Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Generalized Anxiety Disorder","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Seroquel XR"],"phase":"marketed","status":"active","brandName":"Quetiapine Fumarate Sustained Release","genericName":"Quetiapine Fumarate Sustained Release","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Quetiapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Major depressive disorder (adjunctive therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}